274 related articles for article (PubMed ID: 31622621)
1. Therapeutic Targeting of the Colorectal Tumor Stroma.
Fridman WH; Miller I; Sautès-Fridman C; Byrne AT
Gastroenterology; 2020 Jan; 158(2):303-321. PubMed ID: 31622621
[TBL] [Abstract][Full Text] [Related]
2. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
Georganaki M; van Hooren L; Dimberg A
Front Immunol; 2018; 9():3081. PubMed ID: 30627131
[TBL] [Abstract][Full Text] [Related]
3. The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine.
Riley JM; Cross AW; Paulos CM; Rubinstein MP; Wrangle J; Camp ER
Cancer; 2018 Apr; 124(8):1650-1659. PubMed ID: 29315503
[TBL] [Abstract][Full Text] [Related]
4. Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?
Goedegebuure RSA; de Klerk LK; Bass AJ; Derks S; Thijssen VLJL
Front Immunol; 2018; 9():3107. PubMed ID: 30692993
[TBL] [Abstract][Full Text] [Related]
5. Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment.
Yu G; Wu Y; Wang W; Xu J; Lv X; Cao X; Wan T
Cell Mol Immunol; 2019 Apr; 16(4):401-409. PubMed ID: 29622799
[TBL] [Abstract][Full Text] [Related]
6. Anti-Angiogenics: Their Value in Colorectal Cancer Therapy.
Seeber A; Gunsilius E; Gastl G; Pircher A
Oncol Res Treat; 2018; 41(4):188-193. PubMed ID: 29562227
[TBL] [Abstract][Full Text] [Related]
7. New Roles for Fusobacterium nucleatum in Cancer: Target the Bacteria, Host, or Both?
Slade DJ
Trends Cancer; 2021 Mar; 7(3):185-187. PubMed ID: 33309240
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.
Mehrvarz Sarshekeh A; Overman MJ; Kopetz S
Future Oncol; 2018 Aug; 14(18):1869-1874. PubMed ID: 29473436
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in colorectal cancer.
Agarwal P; Le DT; Boland PM
Adv Cancer Res; 2021; 151():137-196. PubMed ID: 34148613
[TBL] [Abstract][Full Text] [Related]
10. Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy.
Kashyap AS; Schmittnaegel M; Rigamonti N; Pais-Ferreira D; Mueller P; Buchi M; Ooi CH; Kreuzaler M; Hirschmann P; Guichard A; Rieder N; Bill R; Herting F; Kienast Y; Dirnhofer S; Klein C; Hoves S; Ries CH; Corse E; De Palma M; Zippelius A
Proc Natl Acad Sci U S A; 2020 Jan; 117(1):541-551. PubMed ID: 31889004
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance and new therapies in colorectal cancer.
Van der Jeught K; Xu HC; Li YJ; Lu XB; Ji G
World J Gastroenterol; 2018 Sep; 24(34):3834-3848. PubMed ID: 30228778
[TBL] [Abstract][Full Text] [Related]
12. Combination of Fruquintinib and Anti-PD-1 for the Treatment of Colorectal Cancer.
Wang Y; Wei B; Gao J; Cai X; Xu L; Zhong H; Wang B; Sun Y; Guo W; Xu Q; Gu Y
J Immunol; 2020 Nov; 205(10):2905-2915. PubMed ID: 33028620
[TBL] [Abstract][Full Text] [Related]
13. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer.
Chen Y; Zheng X; Wu C
Front Immunol; 2021; 12():792691. PubMed ID: 34925375
[TBL] [Abstract][Full Text] [Related]
14. ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application.
Hu G; Tu W; Yang L; Peng G; Yang L
Cancer Lett; 2020 Mar; 473():148-155. PubMed ID: 31911080
[TBL] [Abstract][Full Text] [Related]
15. The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target.
Gambardella V; Castillo J; Tarazona N; Gimeno-Valiente F; Martínez-Ciarpaglini C; Cabeza-Segura M; Roselló S; Roda D; Huerta M; Cervantes A; Fleitas T
Cancer Treat Rev; 2020 Jun; 86():102015. PubMed ID: 32248000
[TBL] [Abstract][Full Text] [Related]
16. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab for the treatment of colorectal cancer.
Smith KM; Desai J
Expert Rev Anticancer Ther; 2018 Jul; 18(7):611-618. PubMed ID: 29792730
[TBL] [Abstract][Full Text] [Related]
18. Genomics and emerging biomarkers for immunotherapy of colorectal cancer.
Kather JN; Halama N; Jaeger D
Semin Cancer Biol; 2018 Oct; 52(Pt 2):189-197. PubMed ID: 29501787
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches.
Tintelnot J; Stein A
World J Gastroenterol; 2019 Aug; 25(29):3920-3928. PubMed ID: 31413527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
